CLINICAL TRIALS PROFILE FOR AVANAFIL
✉ Email this page to a colleague
All Clinical Trials for avanafil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00769041 ↗ | A Thorough EKG Safety Study of TA-1790 (Avanafil) | Completed | Covance | Phase 1 | 2008-10-01 | This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers. |
| NCT00769041 ↗ | A Thorough EKG Safety Study of TA-1790 (Avanafil) | Completed | VIVUS, Inc. | Phase 1 | 2008-10-01 | This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers. |
| NCT00770042 ↗ | To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil | Completed | VIVUS, Inc. | Phase 1 | 2008-10-01 | This study is being conducted to examine the effect of three CYP3A4 inhibitors (ketoconazole, erythromycin and ritonavir) on the single dose pharmacokinetics of avanafil. Ketoconazole and ritonavir are potent inhibitors of CYP3A4 and erythromycin is a moderate CYP3A4 inhibitor. Any interaction that is observed would be predictive of other inhibitors of CYP3A4. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for avanafil
Condition Name
Clinical Trial Locations for avanafil
Trials by Country
Clinical Trial Progress for avanafil
Clinical Trial Phase
Clinical Trial Sponsors for avanafil
Sponsor Name
